Cancer Research Technology (CRT; London), the technology commercialization arm of Cancer Research UK, has spun out a new start-up, Acublate, to take forward a next-generation high intensity focused ultrasound (HIFU) surgery device that could offer safety and performance advantages over existing HIFU systems for treating solid tumors.